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Gene knockout by homologous recombination is a popular method to study gene functions
in the mouse in vivo. However, its lack of temporal control has limited the interpretation
of knockout studies because the complete elimination of a gene product often alters
developmental processes, and can induce severe malformations or lethality. Conditional
gene knockdown has emerged as a compelling alternative to gene knockout, an approach
well-established in vitro but that remains challenging in vivo, especially in the adult
brain. Here, we report a method for conditional and cell-specific gene knockdown in the
mouse brain in vivo that combines Cre-mediated RNA interference (RNAi) with classical
and lentivirus-mediated transgenesis. The method is based on the inducible expression
of a silencing short hairpin RNA (shRNA) introduced in mice by lentivirus-mediated
transgenesis, and on its activation by excision of a floxed stop EGFP reporter with an
inducible Cre recombinase expressed in astrocytes or in neurons. This dual system should
be of broad utility for comparative studies of gene functions in these two cell types in vivo.
Keywords: in vivo gene knockdown, conditional gene knockdown, shRNA, Cre-lox genetics, lentivirus-mediated
transgenesis
INTRODUCTION
Genetic models in the mouse have significantly advanced the
understanding of gene functions, both in physiological and
pathological conditions. Most of the existing models have been
generated by genetic manipulations that lead to a gain- or loss-of-
function of the candidate gene (Aronoff and Petersen, 2006). This
is usually achieved with vector-based overexpression systems,
or by gene targeting like gene knockout or knockin (Capecchi,
2005; Glaser et al., 2005). Recently, RNA interference (RNAi)
has emerged as an alternative approach with the advantage of
decreasing rather than fully eliminating the expression of tar-
get gene(s) (McManus and Sharp, 2002; Paddison and Hannon,
2002). RNAi-based gene knockdown relies on short double-
stranded RNAs (19–21 nucleotides) that target complementary
mRNA sequences, and promote their degradation or inhibit their
translation (McManus and Sharp, 2002; Dykxhoorn et al., 2003).
It can be used in rodents by local or systemic delivery of short-
interfering RNAs (siRNAs) (Thakker et al., 2004), or through
virus-based shRNA expression vectors (Ralph et al., 2005; Singer
et al., 2005; Sapru et al., 2006). Although this approach can
be extremely useful, its efficiency is subjected to variability and
depends on several factors, in particular the degree of sequence
matching with the target DNA, and the level of expression of the
shRNA and the targeted gene. Further, even if it has been used
successfully in cell culture (Elbashir et al., 2001; Brummelkamp
et al., 2002; Lee et al., 2002), it remains challenging in vivo. Thus,
overall, genetic systems for gene silencing have been reported
in the literature (Rubinson et al., 2003; Tiscornia et al., 2003;
Coumoul et al., 2005; Szulc et al., 2006; Dickins et al., 2007;
Delic et al., 2008; Seidler et al., 2008) but are often difficult to
use due to their limitations such as insufficient temporal and
spatial control, and unspecific off-target effects (Scacheri et al.,
2004).
Here, we describe a combinatorial genetic approach to achieve
stable, heritable, and inducible gene knockdown in astrocytes
or neurons in the adult mouse brain in vivo. The approach is
based on the combination of the Cre-loxP system (Sauer and
Henderson, 1989) and a lentiviral vector (Ventura et al., 2004)
that allow the conditional expression of a short hairpin RNA
(shRNA) in specific cells in the brain and its tracing by an EGFP
reporter. We provide a proof of principle for the efficiency and
power of the method for in vivo and ex vivo applications.
RESULTS
ESTABLISHMENT AND VALIDATION OF shRNA-MEDIATED GENE
KNOCKDOWN IN VITRO
To establish a method for gene knockdown in astrocytes or neu-
ronal cells in the mouse brain, we designed interfering small
RNAs against a candidate gene known to be expressed in both
cell types. We selected the gene coding for serine racemase (SR),
a cytoplasmic enzyme that synthesizes D-serine from L-serine
(Wolosker, 2007; Baumgart and Rodriguez-Crespo, 2008). siRNA
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duplexes matching the SR sequence were designed and their
efficiency to knockdown SR expression was evaluated in vitro.
A vector for expressing a flag-tagged SR (pCMV-Tag2-SR) was
cloned, and transiently transfected into human embryonic kidney
cells (Hek293T). In the resulting transfected cells, SR protein was
expressed, and was enriched in the soluble fraction. The expres-
sion level was proportionate to the concentration of the vector
(Figure 1A). Cells expressing SR were then transfected with either
one of four siRNAs (siRNA1–4) against SR (Table S1A). Three
siRNAs (1–3) significantly reduced SR expression in the trans-
fected cells and led to a consistent SR knockdown (Figure 1B).
siRNA3 was selected for use in vivo (Figure S1A). SiRNA4 did not
have any effect on SR expression.
Stable RNAi is best obtained in vivo using vectors expressing
shRNAs (double-stranded) that are processed into siRNAs by the
cellular machinery (McManus and Sharp, 2002; Dykxhoorn et al.,
2003). To constitutively express an shRNA matching siRNA3 in
vivo,we used a pSicoR vector (Ventura et al., 2004) and first tested
its efficiency in cell culture. Consistent with the results obtained
with siRNA duplexes, shRNA3 induced a significant knockdown
of SR in three independent replicates (Figure 1C and Table S1B).
It resulted in a mean decrease in SR expression of 48% (±20%)
and 39% (±23%) with 1:1 and 1:3 plasmid ratios, respectively
(pSicoR-shRNA3:pCMV-Tag2-SR) (Figure S1B). The effect was
specific to SR since no change in β-actin expression was detected.
Control scrambled shRNA or shRNA4 matching siRNA4 had no
effect on SR expression.
GENERATION OF MICE CARRYING A CONDITIONAL shRNA3
EXPRESSION VECTOR BY LENTIVIRUS-MEDIATED TRANSGENESIS
To achieve conditional expression of shRNA3 in the mouse brain
in vivo, we generated transgenic mice by lentivirus-mediated
transgenesis. This method was reported to be highly efficient,
and to allow the rapid and simultaneous generation of multi-
ple independent transgenic lines (Lois et al., 2002). To express
shRNA3, we used a pSico lentiviral vector that was previously
used for conditional gene knockdown based on the Cre-loxP
system (Sauer and Henderson, 1989; Ventura et al., 2004). An
oligonucleotide encoding shRNA3 was inserted downstream of
the ubiquitous U6 RNA polymerase III promoter and of a floxed
stop/reporter cassette encoding EGFP under the ubiquitous CMV
promoter (Figure 2A). Lentivirus carrying the pSico-shRNA3
construct was produced in Hek293T cells and used to generate
transgenic mice by injection of the lentiviral particles into the
perivitelline space of fertilized mouse oocytes. Lentiviral transge-
nesis was achieved using transgenic oocytes carrying a CreERT2
(an inducible form of Cre) transgene driven by a glial fibril-
lary acidic protein (GFAP) promoter. These mice which carry
GFAP-CreERT2 express CreERT2 in astrocytes and were gener-
ated by classical pronuclear injection (Feil et al., 1996; Hirrlinger
et al., 2006). The goal of this strategy was to avoid the need for
subsequent back-crossing of individual pSico-shRNA3 founder
mice with mice carrying the GFAP-CreERT2 transgene. In the
resulting double transgenic animals, CreERT2 is expected to lead
to the excision of the floxed/stop EGFP reporter cassette from
FIGURE 1 | Establishment of siRNA-dependent knockdown of a
target gene (SR) in vitro. (A) Western blot showing luciferase and
SR expression in Hek293T cells transfected with 50, 100, and 150 ng
of pCMV-Tag2-SR encoding SR fused to an epitope peptide (flag).
Mock, empty pCMV-Tag2 plasmid; Control, pCMV-Tag2 plasmid carrying
a tagged firefly luciferase. Optimal cell delivery was determined by
comparing siRNA-Alexa 488 fluorescence distribution (not shown).
(B) Silencing efficiency of SR siRNAs. Western blot showing SR
expression in Hek293T cells co-transfected with pCMV-Tag2-SR and
siRNAs 1–4, or control pCMV-Tag2 (Control). Non-transfected cells were
used as negative control. (C) SR knockdown by shRNA3. Western blot
showing SR expression in Hek293T cells co-transfected with
pCMV-Tag2-SR, pSicoR-shRNAsc encoding a scrambled shRNA and
pSicoR-shRNA3 (left panel), or pSicoR-shRNA4 (right panel).
pCMV-Tag2-SR was co-transfected with the empty vector pCDNA3.1 as
control. β-actin was used as loading control.
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FIGURE 2 | Inducible and cell-specific gene knockdown in vivo. (A)
Schematic representation of the genetic system used to achieve
inducible and astrocyte- or neuron-specific shRNA expression in the adult
mouse brain. pSico-shRNA3 × GFAP-CreERT2 (1) and pSico-shRNA3 ×
CaMKIIα-CreERT2 mice (2) express a Cre recombinase fused to a
mutated version of the human estrogen receptor ligand-binding domain
(ERT2). CreERT2 requires 4-hydroxytamoxifen (active tamoxifen
metabolite) to be active. pSico-shRNA3 × CaMKIIα-Cre mice (3) express
a constitutively active Cre recombinase. CreERT2/Cre expression is under
the control of either the astrocyte-specific GFAP promoter (1) or the
forebrain neuron-specific CaMKIIα promoter (2). Cre or tamoxifen-activated
CreERT2, excise a stop/reporter cassette flanked by loxP sites from the
pSico lentivirus-based vector and switch on shRNA expression. The
synthesized shRNA is then processed into a siRNA by the cellular
machinery, with a predicted siRNA sequence complementary to the
targeted SR mRNA (in red). U6, Pol III promoter; CMV, pol II promoter;
EGFP, enhanced green fluorescent protein; shRNA, small hairpin RNA;
siRNA, small interfering RNA. (B) Picture of a transgenic founder carrying
the pSico-shRNA3 lentiviral construct and showing ubiquitous EGFP
expression, as visualized under UV light.
pSico-shRNA3 in the presence of tamoxifen, and to shRNA3
expression only in astrocytes.
Eleven pups (F0) born from the lentivirus-injected oocytes
after transplantation in foster mothers were genotyped, and eight
were found to carry the pSico-shRNA3 vector (transgenesis effi-
ciency of 72.7%). This high ratio of transgenesis is consistent with
the expected high rate of provirus integration as reported ear-
lier (Lois et al., 2002). The visualization of EGFP signal revealed
that four of the eight founder mice had strong and widespread
EGFP expression (Figure 2B). The eight founders were then used
to establish transgenic lines by breeding with wild-type C57BL/6
mice. On average, 63.5% of the first generation offspring (F1)
was positive for pSico-shRNA3, consistent with the expected inte-
gration of the proviral transgene at multiple chromosomal loci,
including in germ cells (Lois et al., 2002). Further, on average,
half of the progeny was positive for GFAP-CreERT2 (normal
Mendelian inheritance for a transgene integrated in a single locus)
(Table S2A). Two lines (1 and 3) were further bred to wild-type
C57BL/6 mice down to the third generation (F3), and one line
(line 2) down to the fifth generation (F5). These lines showed a
transmission ratio of the pSico-shRNA3 transgene close to 50%
by the third generation, suggesting segregation of the transgene
to a single locus after two backcrosses. It is noteworthy that the
reduction of integration sites down-to-one occurred over only
two generations, possibly because the virus was injected at a low
titer and integrated only into few loci.
Once adult mice carrying the lentiviral transgene were
obtained, we determined the region- and cell-specificity of EGFP
expression in pSico-shRNA3 mice by immunostaining. EGFP
expression was detected throughout the brain (Figure 3A); it was
weak in astrocytes but strong in many neurons including pyra-
midal cells in the cortex (layer II–III, neuronal cell bodies, and
axonal projections) and hippocampus area CA1-CA3, granule
cells in the dentate gyrus, the cerebellum and the olfactory bulbs,
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FIGURE 3 | EGFP expression in mice carrying pSico-shRNA3. (A)
Immunostaining showing EGFP expression (green) in olfactory bulb (OB),
prefrontal cortex (PfCx), cortex and striatum (Cx-Str), hippocampus (Hi), and
cerebellum (Ce). (B) EGFP co-immunostaining with the astroglial marker
GFAP (red, left panels) or the neuronal marker NeuN (red, right panels) in
PfCx, Cx, Hi [area CA1, CA3, dentate gyrus (DG)], and Ce. Scale bar: 10 and
40μm for cerebellum. (C) EGFP expression in astrocytes in hippocampal area
CA1 by co-localization with GFAP after antigen unmasking. Scale bar: 10μm.
spiny neurons in the striatum, and Purkinje neurons (Figures 3B,
S2A). Since EGFP signal was weak in astrocytes, we carried out
further immunostaining using an antigen unmasking method
to confirm the signal. This staining showed a much stronger
and consistent EGFP expression in astrocytes in multiple brain
regions including prefrontal areas, cortex, hippocampus, dentate
gyrus (Figure 3C), confirming that EGFP is expressed in both
glial and neuronal cells.
STABLE, INDUCIBLE, AND CELL-SPECIFIC KNOCKDOWN IN THE ADULT
MOUSE BRAIN IN VIVO
Next, we evaluated the efficiency and specificity of SR knock-
down by shRNA3 in vivo. To test the knockdown in astrocytes or
neurons in the adult brain, we generated double transgenic mice
carrying pSico-shRNA3 and either, GFAP-CreERT2 for knock-
down in astrocytes, or CaMKIIα promoter-CreERT2 or CaMKIIα
promoter-Cre for knockdown in forebrain neurons.
Inducible astrocyte-specific SR silencing in the adult mouse brain
In order to confirm that the conditions were gathered to
achieve SR knockdown in astrocytes, we first examined the
profile and level of expression of CreERT2 in the mice carry-
ing pSico-shRNA3 and GFAP-CreERT2. Quantitative real-time
PCR revealed that CreERT2 mRNA was expressed throughout
the brain, including in prefrontal and cerebral cortex, hip-
pocampus, and cerebellum (Figure 4A). The observed pattern
of expression was consistent with that described previously in
GFAP-CreERT2 mice (Hirrlinger et al., 2006). But despite broad
mRNA expression, CreERT2 protein was detected only in the
hippocampus and cerebellum (with very low level in prefrontal
and cerebral cortex) (Figure 4B), possibly due to posttranscrip-
tional regulation. Consistently, recombination after tamoxifen
treatment was detected in the hippocampus and cerebellum
but only weakly in cortical areas (Figure 4C). In the cerebel-
lum, CreERT2-dependent recombination resulted in a decrease
in SR mRNA (39.49% ± 3.83) and protein (69.82% ± 34.05),
indicating functional shRNA3 expression and gene silencing
(Figures 4D,E). However, in the hippocampus, no SR knockdown
was detected despite CreERT2 expression. Although surprising,
this result is consistent with a previous report showing a disso-
ciation between gene recombination and silencing (Turlo et al.,
2010). Importantly, the observed recombination was specific to
astrocytes and did not occur in neurons as EGFP expression
was unaltered in neurons after tamoxifen treatment (Figure 5A).
Finally, no recombination was detected in mice injected with
vehicle (Figure 4C).
To confirm that the observed recombination was restricted
to astrocytes, we performed EGFP staining in primary astro-
cytic cultures from pSico-shRNA3 × GFAP-CreERT2 mice. In
these cultures, activation of CreERT2 by 4-hydroxytamoxifen, a
metabolite that is more efficient than tamoxifen in dissociated
cells, induced optimal SR recombination and suppressed EGFP
expression as observed by a loss of EGFP signal (Figure 5C).
In contrast, no recombination was detected in astrocytes in the
absence of 4-hydroxytamoxifen, or in astrocytes frommice carry-
ing only pSico-shRNA3 or GFAP-CreERT2 (Figure 5B).
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FIGURE 4 | Inducible and astrocyte-specific gene knockdown in the adult
mouse brain. (A) RT-PCR showing CreERT2 expression in pSico-shRNA3 ×
GFAP-CreERT2 (EGFP+/CreERT2+) mice. No expression was detected in the
absence of CreERT2 (EGFP+/CreERT2− control mice). –RT, Non-reverse
transcribed sample. (B) Immunoblot analysis of CreERT2 protein in
pSico-shRNA3 × GFAP-CreERT2 (EGFP+/CreERT2+) mice. (C) PCR showing
Cre-mediated recombination induced by tamoxifen treatment in different
brain structures in pSico-shRNA3 × GFAP-CreERT2 mice. No recombination
was detected in mice not treated with tamoxifen (vehicle). EGFP−/CreERT2+
mice were used as negative control, and GAPDH as loading control. (D)
Real-time quantitative RT-PCR showing a significant decrease in SR mRNA
expression in cerebellum in pSico-shRNA3 × GFAP-CreERT2 adult mice
(EGFP+/CreERT2+, n = 8) compared to control mice (EGFP+/CreERT2− and
EGFP−/CreERT2+, n = 8). β-actin was used as internal control. (E) SR protein
level is significantly decreased in cerebellum of pSico-shRNA3 ×
GFAP-CreERT2 adult mice (EGFP+/CreERT2+, n = 5) relative to control mice
(EGFP+/CreERT2− and EGFP−/CreERT2+, n = 5). Immunoblot analysis with
15μg of total proteins loaded for prefrontal cortex (PfCx), cortex (Cx),
hippocampus (Hi), and 25μg for cerebellum (Ce). β-actin was used as a
loading control. ∗p < 0.05.
Inducible and constitutive neuron-specific gene silencing in the
adult mouse brain
We next tested whether the mice carrying pSico-shRNA3 also
allow SR knockdown in neurons. For this, we crossed them with
transgenic mice expressing CreERT2 (line 1302, unpublished)
or Cre (line 2834) (Schweizer et al., 2003) under the control
of the forebrain neuron-specific CaMKIIα promoter (both lines
generated by conventional pronuclear injection) (Figure 2A and
Table S2B). The resulting double mutant animals carry pSico-
shRNA3 and either one of Cre transgenes, and are expected
to have SR knockdown only in forebrain neurons. Quantitative
RT-PCR revealed that in these mice, CreERT2 or Cre was
expressed in prefrontal cortex, cerebral cortex, and hippocam-
pus (Figures 6A,B), and led to gene recombination in these
areas (Figure 6D), consistent with the forebrain specificity of
the CaMKIIα promoter (Mayford et al., 1996; Schweizer et al.,
2003). However, CreERT2 was also detected at low level in
the cerebellum (Figures 6A,C), as shown by a previous report
(Erdmann et al., 2007), but did not induce any recombination.
There was also no recombination in mice injected with vehicle,
demonstrating tight control of CreERT2 activity by tamoxifen.
Recombination led to a significant reduction in the level of SR
protein (79.8 ± 28% in hippocampus and 34.8 ± 6% in cere-
bellum) (Figure 6F). However, SR expression was not altered in
the prefrontal and cerebral cortex despite evidence for recombi-
nation, suggesting again a dissociation between CreERT2 expres-
sion and DNA recombination. SR expression was nonetheless
reduced in the olfactory bulb and striatum (Figure S2B). In
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FIGURE 5 | Cre-mediated recombination in astrocytes and neurons.
(A) Immunohistochemical analysis of EGFP expression in tamoxifen-
treated pSico-shRNA3 × GFAP-CreERT2 mice. EGFP (green) and GFAP
(red) co-immunostaining in prefrontal cortex (PfCx), cortex (Cx),
hippocampus (CA1, CA3, DG), and cerebellum (Ce). Scale bar: 40μm.
(B) PCR showing Cre-mediated recombination (left panel)
in pSico-shRNA3 × GFAP-CreERT2 primary astrocytes by
4-hydroxytamoxifen treatment (Tam). No recombination is detected in
non-treated cells (No Tam) or in astrocytes from mice carrying
pSico-shRNA3 and GFAP-CreERT2 alone. Genotyping PCR from
pSico-shRNA3 × GFAP-CreERT2, pSico-shRNA3, and GFAP-CreERT2
astrocytes (right panel). (C) EGFP and GFAP co-staining in
pSico-shRNA3 × GFAP-CreERT2 astrocytes treated with
4-hydroxytamoxifen (Tam) compared to non-treated astrocytes (No Tam).
pSico-shRNA3 × CaMKIIα-Cre mice, DNA recombination was
also observed in forebrain structures and correlated with the level
and pattern of Cre expression (Figure 6E), as previously observed
(Schweizer et al., 2003). This was associated with a significant
decrease in SR mRNA level in prefrontal (36.1 ± 7.8%) and cere-
bral cortex (35.3 ± 5%) when compared to wild-type mice. As
expected, SR mRNA was not changed in the cerebellum; unex-
pectedly, it was not changed in the hippocampus despite obvious
DNA recombination in this region (Figure 6G). Consistent with
the pattern of mRNA expression, SR protein was significantly
reduced in prefrontal cortex (62.3 ± 9%) and cortex (66 ± 16%),
but not significantly in cerebellum or hippocampus (Figure 6H).
In conclusion, the reduction in SR mRNA and protein obtained
in pSico-shRNA3 × CaMKIIα-CreERT2 and pSico-shRNA3 ×
CaMKIIα-Cre mice suggest a silencing mechanism mediated by
shRNA and involving mRNA degradation (McManus et al., 2002;
Song et al., 2004).
Next, we addressed the cell specificity of DNA recombina-
tion and SR knockdown. DNA recombination visualized by
a loss of EGFP signal was observed selectively in neurons in
prefrontal cortex, cerebellar cortex, and hippocampus (CA1,
CA3, and DG) in pSico-shRNA3 × CaMKIIα-CreERT2 treated
with tamoxifen and in pSico-shRNA3 × CaMKIIα-Cre mice
(Figures 7, S3). However, EGFP fluorescence was not fully elim-
inated in CA1/CA3 pyramidal neurons and DG granular cells
in pSico-shRNA3 × CaMKIIα-Cre mice, suggesting incomplete
recombination in these neurons. This may explain why the reduc-
tion in SR level in the hippocampus was not significant in this
line. A loss of EGFP fluorescence was also detected in Purkinje
cells and granule neurons in the cerebellum in pSico-shRNA3 ×
CaMKIIα-CreERT2 mice (Figures 7, S3). It is also possible that
recombination occurred in other neurons expressing EGFP only
weakly, but was below detection level.
Overall, these data demonstrate the efficacy of our combined
system for inducible or constitutive astrocyte- or neuron-specific
gene knockdown in the adult mouse brain.
LENTIVIRAL TRANSDUCTION OF ASTROCYTES AND NEURONS
IN VITRO, AND IN THE MOUSE BRAIN IN VIVO
Lentiviruses have been successfully used in cell culture and in
the brain in vivo for gene delivery in non-dividing cells (Naldini
et al., 1996; Bemelmans et al., 2006; Sapru et al., 2006; Szulc
et al., 2006). We examined whether, in addition to being efficient
for transgenesis, the pSico-shRNA3 lentivirus was also suitable
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FIGURE 6 | Constitutive and inducible neuron-specific gene
knockdown in the adult mouse brain. (A,B) RT-PCR showing Cre
expression in pSico-shRNA3 × CaMKIIα-CreERT2 (EGFP+/CreERT2+) (A)
and pSico-shRNA3 × CaMKIIα-Cre (EGFP+/Cre+) forebrain structures (B).
No expression is detected in the absence of Cre (EGFP+/CreERT2− and
EGFP+/Cre− control mice). –RT, Non-reverse transcribed sample. (C)
Immunoblot analysis of CreERT2 protein level in pSico-shRNA3 ×
CaMKIIα-CreERT2 (EGFP+/CreERT2+) mice. β-actin was used as a loading
control. (D) Cre-mediated recombination is induced by tamoxifen
treatment in different pSico-shRNA3 × CaMKIIα-CreERT2 brain structures.
No recombination occurs in vehicle treated pSico-shRNA3 ×
CaMKIIα-CreERT2 mice. EGFP−/CreERT2− mice were used as negative
control. (E) Cre is constitutively active and leads to recombination in
pSico-shRNA3 × CaMKIIα-Cre (EGFP+/Cre+) forebrain structures, whereas
no recombination occurs in mice lacking Cre (EGFP+/Cre−) or
pSico-shRNA3 (EGFP−/Cre+). GAPDH was used as loading control. (F)
Immunoblot analysis showing decreased SR level in hippocampus and
cerebellum of pSico-shRNA3 × CaMKIIα-CreERT2 adult mice upon
tamoxifen treatment (EGFP+/CreERT2+, n = 5). Quantification relative to
control mice (EGFP+/CreERT2− and EGFP−/CreERT2+, n = 8). 15μg of
total proteins were loaded for prefrontal cortex (PfCx), cortex (Cx),
hippocampus (Hi), and 25μg for cerebellum (Ce). β-actin was used as
loading control. (G) Real-time quantitative RT-PCR showing significantly
decreased SR mRNA expression in prefrontal cortex and cortex of
pSico-shRNA3 × CaMKIIα-Cre adult mice (EGFP+/Cre+, n = 8) compared
to control mice (EGFP+/Cre− and EGFP−/Cre+, n = 11). β-actin was used
as an internal control. (H) Immunoblot analysis showing decreased SR
level in PfCx, Cx, and Hi of pSico-shRNA3 × CaMKIIα-Cre adult mice
(EGFP+/Cre+, n = 8). Quantification relative to control mice (EGFP+/Cre−
and EGFP−/Cre+, n = 8). 15μg of total proteins were loaded for PfCx,
Cx, Hi, and 25μg for cerebellum (Ce). β-actin was used as loading
control. #p = 0.07, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
for cell infection in vitro, and in the adult mouse brain in vivo.
We evaluated pSico-shRNA3 efficacy and cellular tropism using
EGFP expression. In cell culture, the virus showed a high infection
rate and broad tropism, and led to EGFP expression in primary
neurons, mixed primary neuronal cultures and primary astro-
cytes 24 h after infection (Figures S4A–C). Likewise in vivo, the
stereotactic injection of pSico-shRNA3 led to EGFP expression 6
weeks after injection in the hippocampus (Figures S5A,B), and
10 days after injection in the striatum (Figure S5C). Similarly,
when injected in the rat brain in vivo, pSico-shRNA3 showed
high cellular transduction in both astrocytes and neurons (data
not shown), indicating its efficacy and usefulness in different
species.
DISCUSSION
Here, we report the establishment of a combinatorial genetic
approach for heritable gene silencing in the mouse brain in vivo.
The method is based on the combination of Cre/loxP technol-
ogy and a lentiviral vector encoding a loxP-controlled shRNA,
allowing inducible knockdown of specific target genes in astro-
cytes or neurons in the adult mouse brain. Because this sys-
tem uses independent mouse lines, it is versatile and can be
applied to any candidate gene in different cell types and brain
regions. It can exploit existing shRNA libraries covering mam-
malian transcripts (Paddison et al., 2004; Root et al., 2006)
and any available CreERT2 or Cre transgenic line (Gaveriaux-
Ruff and Kieffer, 2007) (see http://jaxmice.jax.org/research/
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FIGURE 7 | Visualization of Cre-mediated recombination in neurons.
EGFP (green) and NeuN (red) co-immunostaining in prefrontal cortex (PfCx),
cortex (Cx), hippocampus (Hi: CA1, CA3, DG), and cerebellum (Ce). Sections
from tamoxifen-treated pSico-shRNA3 × CaMKIIα-CreERT2 and
pSico-shRNA3 × CaMKIIα-Cre mice were imaged by Laser Scanning Confocal
Microscopy (LSCM). Decreased EGFP expression is observed in neurons
from all structures expressing Cre in pSico-shRNA3 × CaMKIIα-CreERT2 and
pSico-shRNA3 × CaMKIIα-Cre mice. Scale bar: 10 and 20μm for cerebellum.
cre/strainlist.html or http://nagy.mshri.on.ca/cre/Search.php for
Jackson and Nagy databases). In this study, we generated a novel
line expressing CreERT2 in forebrain neurons. This CaMKIIα
promoter-CreERT2 line is of particular interest because it allows
more extended recombination than a previously reported line
(Erdmann et al., 2007).
This study demonstrates the usefulness of a dual system
for parallel recombination in astrocytes or neurons in dif-
ferent mice, for comparative analyses of the impact of gene
knockdown in these two cell types. Such cellular distinction
is instrumental for in vivo functional studies of genes whose
role in astrocytes or neurons is not known, such as the
selected candidate, SR. Together with the inducibility of the
knockdown, this cellular specificity provides a major advantage
over conventional knock-out methods. It has the potential to
limit compensatory effects and circumvent the potential neg-
ative effects of gene knockdown on developmental processes,
although compensatory effects can potentially still occur after
inducible expression (Alvarez et al., 2006). Further, the fact
that the candidate gene is knocked-down, rather than knocked-
out, is advantageous when trying to recapitulate a disease state
caused by hypomorphic mutation(s). It is also an advantage
for dissecting out the function of candidate genes whose full
deficiency can alter vital cellular processes and possibly induce cell
death.
Another advantage of this approach is the rapidity of the gen-
eration of the mutant mice resulting from the high efficiency of
lentivirus-mediated transgenesis, and its high rate of success com-
pared to conventional pronuclear microinjection (Gordon et al.,
1980; Auerbach, 2004). Thus, oocyte survival (92/98, 94% vs.
60–80% for pronuclear injection) and the fraction of injected
oocytes resulting in born pups (23/98, 23% vs. 10–20% in clas-
sical transgenesis) are overall higher than usually achieved with
pronuclear microinjection (Auerbach, 2004). The integration rate
of the transgene is also higher [8/11 pseudofounders (72.7%) for
pSico-shRNA3 vs. 20–25% (Auerbach, 2004) i.e., 12/55 pseudo-
founders for CaMKIIα-CreERT2]. Injection into the perivitelline
space of fertilized zygotes is also technically less challenging,
and is more amenable to application to different mouse strains
such as C57BL/6, to genetically engineered oocytes (transgenic
GFAP-CreERT2 here), and to other species such as rat. Part of its
efficiency is attributed to the rapid and multiple integration rate
of lentiviral vectors (Naldini et al., 1996) particularly in dividing
cells (Park et al., 2000), which results in the generation of multi-
ple founders in a single injection (Lois et al., 2002). We observed
an overall high rate of segregation of the pSico-shRNA3 vector
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in the eight F1 mouse lines studied, which allowed us to isolate
single transgene loci within a few backcrosses (about three). The
characteristics of each mouse line regarding transgene integration
site(s) and copy number have not been systematically analyzed,
thus the influence of the integration site on expression and the
stability of the transgene over generations cannot be predicted for
each line. Such parameters however need to be determined for
gene function studies when using this approach.
Further to demonstrating the usefulness of the pSico construct
for lentivirus-mediated transgenesis, this study also establishes its
utility in cell culture, and in the brain in vivo after stereotactic
injection. Such different applications open up the possibility to
carry out local, cell-specific, and stable gene knockdown in any
mice expressing Cre as a transgene, or delivered by other means
such as viral vectors (Sinnayah et al., 2004). The efficiency of pSico
in primary neuronal and astroglial cultures further demonstrates
its cellular tropism in these cell types. Such tropism is postu-
lated to originate from the vesicular stomatitis virus glycoprotein
(VSV-G) envelope, found in human immunodeficiency virus type
1 (HIV-1), used for the pSico lentivirus (Li et al., 2012). The U6
and CMV promoters used in the pSico construct show different
cellular specificity between brain regions (Makinen et al., 2006),
possibly due to variegation effects. It is therefore possible that
some EGFP-negative cells express shRNA3 upon Cre-dependent
gene recombination. Conversely, some EGFP-positive cells may
not express shRNA3 despite Cre-dependent gene recombination.
Although Cre-dependent gene recombination with loss of EGFP
fluorescence can be partially visualized, Cre-dependent gene
recombination and shRNA expression need to be independently
verified, as done in this study. Immunostaining using a Cre-
specific antibody could be an appropriate alternative to exam-
ine the spatial distribution of Cre expression. The dissociation
between CreERT2 expression, DNA recombination, and protein
knockdown observed in this study may be explained by differ-
ent factors including variable level of Cre expression, different
recombination efficiency, or the presence of Cre-recombination
episomal products (Hirrlinger et al., 2006).
While gene knockdown based on siRNA expression from a
plasmid encoding shRNA has great potential in vivo, many impor-
tant steps need to be considered for selective and efficient RNAi
(Cullen, 2006). First, proper design and selection of specific siR-
NAs is essential, and has to follow strict rules (Reynolds et al.,
2004; Grimm et al., 2006; Pei and Tuschl, 2006). These rules are
generally implemented in publicly available softwares for shRNA
or siRNA design, but need to be carefully followed. Second, since
silencing efficacy in vivo is difficult to predict based on in silico
siRNA design, each siRNA has to be tested and validated in vitro
before use in vivo. Such validation also serves to exclude poten-
tial compensatory mechanisms or unspecific responses (Scacheri
et al., 2004) (off-target effects) resulting for instance from the
activation of interferon pathways (Bridge et al., 2003). Here,
using dsRNAs ≤30 bp, that was previously suggested to circum-
vent unspecific response (Sledz et al., 2003; Reynolds et al.,
2006), helped limit unspecificity. Careful control analyses con-
firmed that the level of unrelated targets such as GAPDH and
β-actin was also not altered, suggesting no major off-target effect
of shRNA processing in vivo. It may result from the moderate
shRNA expression, which may have also prevented cell toxicity.
Finally, gene knockdown efficiency may vary from individual to
individual and thereby introduce phenotypic variability between
individuals. In such case, it may be necessary to quantify the level
of gene knock-down in each individual and relate it to pheno-
typic responses in a way to properly evaluate the effects of the
manipulation.
In summary, this study is the first to report a genetic system
that allows heritable gene knockdown in astrocytes or neurons in
the mouse brain in vivo. It has all features of the methodologies
combined therein—inducibility, tissue- and cell-type specificity,
facilitated monitoring, and easy andmultiple applications includ-
ing transgenesis, stereotactic injection, and in vitro transduction
of primary cells. These features, in combination with the a grow-
ing number of CreERT2 and Cre mouse lines available make this
approach an extremely useful tool to study neuronal and brain
physiology. Additional guidelines on the use of RNAi technol-
ogy for gene function studies can also be found in the literature
(Moffat et al., 2007).
METHODS
CONSTRUCTS, DESIGN OF SHORT HAIRPIN RNAs, AND LENTIVIRUS
PRODUCTION
SR (GenBank accession number AF148321) was amplified from
a mouse cDNA brain library (Ambion PCR-ready mouse brain
cDNA) by PCR with the following primers (forward: 5′-
CGGGATCCGAGGCAGCAGAGAACCATGT-3′ and reverse: 5′-
CCCAAGCTTAGAGACAATCTTGCCTGAATTT-3′) to generate
BamHI and HindIII restriction sites. The PCR product was puri-
fied, cloned into pCR2.1-TOPO plasmid (Invitrogen), digested
with BamHI and HindIII restriction enzymes, and ligated into
pCMV-Tag2 mammalian expression plasmid (Stratagene) to
obtain pCMV-Tag2-SR carrying SR cDNA fused to a syn-
thetic epitope peptide (FLAG tag) in N-terminal. pSicoOligo-
maker 1.5 program (http://web.mit.edu/jacks-lab/protocols/
pSico.html) was used to design mouse SR shRNA oligos (see
Table S1B). A scrambled shRNA not complementary to any
mouse or human sequence was used as control (Flygare et al.,
2005). shRNAs 3, 4 and scrambled shRNAs were cloned into
pSicoR, and shRNA 3 into pSico (Jacks lab, MIT) according
to Jackson’s lab protocol to generate pSicoR-shRNA3, pSicoR-
shRNA4, pSicoR-shRNAsc, and pSico-shRNA3. Constructs were
verified by sequencing. pSico-shRNA3, the packaging encod-
ing vector psPAX2 and the envelope encoding vector pMD2.G
(obtained from Dr. Didier Trono, EPFL Lausanne) were used
for lentivirus production (see http://tronolab.epfl.ch/page58122.
html for details). Viral particles were titrated by FACS analysis of
infected Hek293T cells.
CELL CULTURE AND TRANSFECTION ASSAYS
Hek293T cells were cultured in standard conditions and trans-
fected with pCMV-Tag2-SR (50, 100, and 150 ng/∼2 × 105 cells),
pCMV-Tag2 control (carrying the firefly luciferase gene), pCMV-
Tag2 (empty vector; mock plasmid), pSicoR-shRNA3, pSicoR-
shRNA4, and pSicoR-shRNAsc plasmids (150 ng/∼2 × 105 cells)
using FuGENE 6 (Roche; see Table S1B) according to the manu-
facturer’s protocol. siRNA duplexes (Qiagen) were co-transfected
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(50 and 150 ng/∼2 × 105 cells) with pCMV-Tag2-SR (50 ng/∼
2 × 105 cells) using X-tremeGENE reagent (Roche). Plasmid
and siRNA transfection efficiency was evaluated by fluores-
cence obtained from pSicoR-shRNAs and siRNA Alexa Fluor 488
(Qiagen; 500 ng/∼ 2 × 105 cells), respectively. Primary astroglial
cultures were obtained by isolating astrocytes from P6 mouse
brains plated on poly-L-lysine-coated (Sigma) glass coverslips
and cultivated in DMEM (Gibco) containing 10% fetal bovine
serum (Invitrogen).
GENERATION OF TRANSGENIC MICE
Lentivirus-mediated transgenesis
Transgenic mice carrying pSico-shRNA3 were generated by
microinjection of lentiviral particles (∼100 pl, 2.5 × 108 TU/ml)
into the perivitelline space of fertilized one-cell oocytes isolated
from four heterozygous GFAP-CreERT2 superovulated females
(98 eggs, FVB/N background provided by Dr. Frank Kirchhoff,
Göttingen) (Hirrlinger et al., 2006). At the blastocyst stage (after
3 days in culture in vitro), the 92 embryos that survived were
implanted into the oviducts of 4 pseudo-pregnant C57BL/6 foster
females. Resulting offspring was genotyped by PCR using primers
complementary to EGFP (present on pSico-shRNA3). Positive
animals were backcrossed to C56BL/6/J mice, or to CaMKIIα-
CreERT2 (line 1302, see below) or CaMKIIα-Cre (line 2834)
(Schweizer et al., 2003) mice. Genotyping was performed using
EGFP F2 (5′-CTA TAT CAT GGC CGA CAA GC-3′) and R2
(5′-ACT GGG TGC TCA GGT AGT GG-3′) primers for pSico-
shRNA3 transgene, and pNN3050 (5′-CGA TTC TAG AAT TCG
CTG TCT GC-3′) and Cre antisense (5′-CAG GGT GTT ATA
AGC AAT CCC-3′) primers for CreERT2 and Cre transgene
amplification.
Classical transgenesis
CaMKIIα-CreERT2 mice were generated by microinjection into
fertilized mouse oocytes (C57BL/6/JXDBA hybrid) with a recom-
binant transgene cloned as follows. CreERT2 cDNA was excised
from the vector pBSII SK+ (generously provided by Dr. Philipp
Berger) by SpeI/KpnI digestion and inserted into the BamHI site
of pNN265 (Michalon et al., 2005). An hFGF2 IRES sequence
excised from pCRFL plasmid (gift from Prof. A. C. Prats) by
NarI/SpeI digestion was blunt-ended using T4 polymerase (New
England Biolabs) and introduced into the SalI site of pNN265
CreERT2. A NotI fragment was excised (5022 bp) from this
recombinant vector and introduced into the NotI site of pMM403
containing the CaMKIIα promoter. SfiI digest resulted in a
13,049 bp fragment used for microinjection. 12 founders (out of
55 pseudo-founders) were obtained, 7 of which transmitted the
transgene to their offspring, and gave rise to 7 independent lines.
F1 animals were backcrossed to C57Bl/6J mice. Line 1302 was
used in this study.
TAMOXIFEN TREATMENT
Tamoxifen solution was prepared and administered daily as
previously described (Hirrlinger et al., 2006). Briefly, tamox-
ifen (Sigma-Aldrich) was dissolved in 90% corn oil (Sigma-
Aldrich) and 10% ethanol to a final concentration of 10mg/ml.
Adult mice received intraperitoneal injections (1mg) twice a
day for 5 days. In primary astrocyte cultures, gene recombina-
tion was induced by application of 1μM 4-hydroxytamoxifen
(tamoxifen metabolite) for 48 h. Corn oil/ethanol was used as
carrier.
WESTERN BLOT ANALYSIS
Hek293T cells were harvested 24 and 48 h after transfec-
tion and lysed with NP-40 buffer. After centrifugation, sol-
uble and membrane protein fractions were resolved on 10%
SDS-PAGE and transferred onto a PVDF membrane (BioRad).
Brains were dissected and homogenized using a 26G syringe
in 10mM HEPES, 1mM MgCl2, 5mM EDTA, 0.2% (v/v)
Triton X-100 (Sigma), 10% (v/v) glycerol (Sigma), protease
inhibitor cocktail (Sigma), 250μM PMSF (Sigma), and 15mM
β-mercaptoethanol (Sigma). 15 to 25μg total protein was
resolved on 10% SDS-PAGE and transferred onto a nitrocellu-
lose membrane (BioRad). Membranes were blocked (Rockland
IR blocking buffer, Rockland), and incubated in primary anti-
bodies: anti-mouse flag M2 primary monoclonal antibody
(1:5000; Sigma), anti-mouse SR primary antibody (1:500; BD
Biosciences), rabbit anti-mouse estrogen receptor α (1:500; Santa
Cruz Biotechnology), mouse anti-GFP (1:1000; Invitrogen),
mouse anti-mouse β-actin (1:5000; Sigma), or rabbit anti-
GAPDH (1:1000; Abcam). Membranes were then incubated in
goat anti-mouse IRDye 680 secondary antibody (1:5000; Li-Cor
Biosciences). Band intensity was determined and quantified using
an Odyssey IR scanner (Li-Cor Biosciences). The protein signal
was normalized to β-actin.
QUANTITATIVE REAL-TIME RT-PCR
Total RNA from prefrontal cortex, cortex, hippocampus, cerebel-
lum, and primary astrocytes was extracted using a NucleoSpin
Kit II (Macherey-Nagel), purified with RQ1 DNase (Promega)
and reverse-transcribed using a SuperScript First-Strand
Synthesis System for RT-PCR II (Invitrogen). Quantitative
PCR was performed with a mouse SR-specific Taqman probe
(Mm00489125_m1, Applied Biosystems) and an Applied
Biosystems 7500 Thermal Cycler. Each sample was analyzed in
triplicate and equal amount of cDNA was plated. Values were
chosen in the linear range of amplification, and the comparative
Ct method was used to determine differences in gene expression
between samples. β-actin was used as an internal control for
normalization.
PCR AND RT-PCR
PCRwas performed on cDNA (2μl) using the primers Cre up (5′-
AGG CTA AGT GCC TTC TCT ACA C-3′) and Cre lo (5′-ACC
AGG TTC GTT CAC TCA TGG-3′) for Cre and CreERT2 ampli-
fication, and primers EGFP F2 (5′-CTA TAT CAT GGC CGA
CAA GC-3′) and R2 (5′-ACT GGG TGC TCA GGT AGT GG-3′)
for EGFP. Gene recombination was assessed by PCR on genomic
DNA by using the primers loop-out F (5′-CCC GGT TAA TTT
GCA TAT AAT ATT TC-3′) and loop-out R (5′-CAT GAT ACA
AAG GCA TTA AAG CAG-3′) (Ventura et al., 2004). PCR prod-
ucts were resolved on a 2% agarose gel. cDNA and gDNA quality
and loading were verified with the housekeeping gene GAPDH
using the primers GAPDH F1 (5′-CAC TGA GCA TCT CCC
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TCA CA-3′) and GAPDH R1 (5′-GTG GGTGCAGCG AAC TTT
AT-3′).
IMMUNOFLUORESCENCE
Animals were sacrificed and transcardially perfused with Ringer
solution followed by 4% paraformaldehyde (Sigma) and 15% of
a saturated solution of picric acid in phosphate buffer (0.1M,
pH7.4; flow: 20ml/min). Brains were quickly removed, postfixed
in the same solution and transferred into a 30% sucrose solution.
Sagital or coronal sections (50μm thick) were cut with a cryostat.
Free-floating brain sections were washed in 0.1MPB, blocked and
permeabilized in 0.1M PB, 0.4% Triton X-100 (Sigma), and 10%
heat-inactivated horse serum (HS; Sigma) for 12 h at 4◦C. When
needed, slices were heated in 0.1M Tris pH 8.0, Glycin 50mM at
80◦C for 15min to unmask the reactivity of EGFP antigens. Slices
were then incubated with primary rabbit anti-EGFP (Synaptic
Systems), anti-NeuN (Chemicon), and anti-GFAP (Dako) anti-
bodies (1:1000) for 12 h at 4◦C in 0.1M PB, 0.4% Triton X-100,
and 10% HS. Slices were washed in 0.1M PB, 0.4% Triton X-100
and incubated overnight at 4◦C with goat anti-rabbit FITC and
donkey anti-mouse TRITC fluorescence-conjugated secondary
antibodies (1:1000; Jackson ImmunoResearch). After washing
in 0.1M PB, slices were mounted using Mowiol (Molecular
Probes) and stored in the dark at 4◦C. Primary astroglial cultures
were fixed overnight into a 4% paraformaldehyde/phosphate
buffer solution (0.1M, pH 7.4), washed in 0.1M PB, blocked
and permeabilized in 0.1M PB, 0.4% Triton X-100 (Sigma),
and 10% heat-inactivated horse serum (HS; Sigma) for 12 h
at 4◦C. Low magnification fluorescence images were acquired
with a CoolSNAPK4 digital camera (Roper Scientific) mounted
on an Axiophot microscope (Zeiss) and analyzed using MCID
Elite 7.0 software (MCID). High magnification images were
taken with a Zeiss LSM 410 confocal laser-scanning micro-
scope using lasers pretuned to 543 nm (TRITC) and 488 nm
(FITC), and images were averaged to improve signal-to-noise
ratio.
STATISTICAL ANALYSIS
Data are presented as mean normalized to baseline or con-
trol ± SEM. Paired Student’s t-tests were used to compare non-
normalized data. Statistical significance was set at p ≤ 0.05(∗),
p ≤ 0.01(∗∗), and p ≤ 0.001(∗∗∗).
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Figure S1 | (A) siRNA3 induces SR knockdown. Hek293T cells were
co-transfected with pCMV-Tag2-SR (50 ng) and siRNA3 (50 and 150 ng),
siRNA4 (50 ng), or control siRNA (siRNA Alexa Fluor 488, 50 ng). SR level
in cells transfected with pCMV-Tag2-SR (50 ng) was used as control. (B)
Quantification of SR knockdown induced by shRNA3 in three independent
experiments (#1, 2, and 3). Hek293T cells were co-transfected with
pCMV-Tag2-SR (50 ng) and the empty vector pCDNA3.1 (Control),
pSicoR-shRNAsc (50 ng or 150 ng; ratio 1:1 or 3:1), or pSicoR-shRNA3
(50 ng or 150 ng; ratio 1:1 or 3:1). Values are mean % of SR knockdown
relative to control normalized to β-actin.
Figure S2 | (A) EGFP expression in olfactory bulb granular cells (OB) and
striatal medium spiny neurons (Str) in pSico-shRNA3 × CaMKIIα-CreERT2
mice, as seen by EGFP and NeuN co-localization. Scale bar: 80μm (20×)
and 20μm (80×). (B) SR expression in olfactory bulb and striatum in
pSico-shRNA3 × CaMKIIα-CreERT2 mice (EGFP+/CreERT2+, n = 4).
mRNA level measured by qRT-PCR relative to controls (EGFP+/CreERT2−
and EGFP−/CreERT2+, n = 6).
Figure S3 | Cre-mediated recombination in neurons. Immunohistochemical
analysis of EGFP expression in control mice (pSico-shRNA3) and in
tamoxifen-treated pSico-shRNA3 × CaMKIIα-CreERT2 and pSico-
shRNA3 × CaMKIIα-Cre adult mice. EGFP (green) and NeuN (red)
co-immunostaining in prefrontal cortex (PfCx), cortex (Cx), hippocampus
(CA1, CA3, DG), and cerebellum (Ce). Sections were imaged by LSCM.
Decreased EGFP expression is observed in neurons in all structures
expressing CreERT2 and Cre. Scale bar: 40μm.
Figure S4 | (A) Distribution of EGFP (green) 24 h after infection of mouse
primary neurons (nuclei stained with DAPI; blue fluorescence) with
pSico-shRNA3 lentivirus (2.5 × 106 TU/ml; 3μl/ml culture medium). Scale
bar: 50μm. (B) Lentiviral infection of rat mixed primary neuronal cultures.
Cells (14DIV) were infected with pSico lentivirus (2.5 × 108 TU/ml)
constitutively expressing EGFP. One week after infection, neurons were
immunolabeled with the neuron-specific marker mitochondrial associated
protein-2 (MAP-2), and analyzed for EGFP expression under a confocal
microscope. Arrows indicate neurons (MAP-2/red) stably expressing EGFP
(red and green overlay). Scale bar: 20μm. (C) Lentiviral infection of
primary astrocytes. Astrocytes were infected with pSicoR-shRNA3
lentivirus (1.4 × 108 TU/ml; 20μl/ml culture medium). Seven days after
infection, cells were immunolabeled for GFAP, EGFP, and the nuclear
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marker DAPI (blue dots in merge), and visualized under a fluorescence
microscope. Scale bar: 160μm
Figure S5 | (A) Coronal section of mouse ventral hippocampus (posterior)
stereotactically injected with pSicoR-shRNA3 lentivirus. Brains were
isolated 6 weeks after injection, and fresh-frozen sections were collected
then analyzed under a fluorescence microscope. A: Ipsilateral hemisphere
injected with 2μl lentivirus pSicoR-shRNA3 (6 × 108 TU/ml); Ventral part
coordinates (relative to bregma): AP −3.16mm, ML ±3.00mm, DV −3
to −2mm; dorsal part coordinates: AP −2.30mm, ML ±2.00, DV −1.5
to −1.25mm; volume flow: 0.5μl.min−1). B: Contralateral non-injected
hemisphere (enhanced contrast for identification of hippocampal
structures). Scale bar: 160μm. (B) Western blot analysis of EGFP
expression in hippocampal homogenates three weeks post-injection.
β-actin (bottom) was used as loading control. Control, non-injected
hemisphere. (C) Regional distribution of transduced cells in the medial
striatum 10 days following stereotactic injection of 2μl pSicoR-shRNA3
lentivirus (6 × 108 TU/ml; coordinates (relative to bregma): AP 0.50mm,
ML ±2.00mm, DV: −3 to −2mm; volume flow: 0.5μl.min−1), as revealed
by EGFP fluorescence. Left inset: localization of the injection site. Scale
bar: 500μm.
Table S1 | Double-stranded siRNAs and oligonucleotides for SR silencing.
(A) Four different siRNAs (1–4) complementary to SR mRNA sequence
(target) were designed. Sense and antisense siRNAs are represented.
siRNA Alexa Fluor 488 negative control: siRNA with no homology to any
known mammalian gene and labeled with Alexa Fluor 488 fluorescent dye
for transfection monitoring and optimization. (B) siRNA3 and
siRNA4-based oligos 3 and 4 with targeted SR cDNA sequence. Sense
and antisense sequences for shRNA expression with loop sequence
TTCAAGAGA and 5′ terminal Ts (on sense strand). Predicted sense and
antisense siRNAs after shRNA processing are in bold. Scrambled oligo
coding for an shRNA not targeting any mammalian gene was used as
negative control.
Table S2 | Germline transmission of the proviral transgene pSico-shRNA3
in pSico-shRNA3 × GFAP-CreERT2, CaMKIIα-CreERT2, and CaMKIIα-Cre
mice. The yield of PCR-positive and PCR-negative mice is presented as a
ratio with the corresponding percentage of pSico-shRNA3 and CreERT2 or
Cre transgene segregation. (A) Eight mouse lines were obtained from
pSico-shRNA3 × GFAP-CreERT2 F0 founders (5 females and 2 males) and
backcrossed down to 5 generations. (B) Transgene segregation in
pSico-shRNA3 × CaMKIIα-CreERT2 (F1–5) and pSico-shRNA3 ×
CaMKIIα-Cre mice (F1–3). F1 pSico-shRNA3 × CaMKIIα-CreERT2 mice
(line 1 and 2) were generated by breeding pSico-shRNA+/GFAP-CreERT2−
F2 mice to CaMKIIα-CreERT2 mice (line 1302 females). F1 pSico-
shRNA3 × CaMKIIα-CreERT2 mice (line 1) were generated from
pSico-shRNA+/GFAP-CreERT2− F4 mice (two line 2 females) bred to a
CaMKIIα-Cre mouse (line 2834 male). The pSico-shRNA3 construct was
reliably transmitted in F1–F5 progeny, indicating stable integration and
effective transmission across generations.
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